Liquid Biopsies are gaining acceptance in the Oncology community as a surrogate or complement to the gold standard of tissue biopsy.  A liquid biopsy provides biomarker information that a physician needs to understand in order to choose the best therapy for a patient. 

Biocept is a San Diego, CA based company with cutting edge cancer diagnostics developed to capture and analyze circulating tumor cells (CTCs) as well as cell-free circulating tumor DNA (CtDNA).   The company has 18 patents issued on it’s proprietary technology that it uses to perform testing on patient samples through it’s CLIA and CAP accredited laboratory. 

The company has validated 13 assays and currently markets these tests worldwide. 

The talk will explain the company’s offerings in detail and also cover key points about the very large opportunity to help patients through liquid biopsy. 

Learning Objective 1:Reasons why physicians use liquid biopsy today and where the uses are trending for the future

Learning Objective 2:Biocept technology overview for both CTC and CTDNA capture and biomarker analysis

Learning Objective 3:Validation results for Biocept Target Selector Assays

Learning Objective 4: Partners for clinical validation along with publications, poster and abstract overview